drugset

drugset / Trial / NCT05302843

A Phase 1 Study of BPI-28592 in Subjects With Advanced Solid Tumors

NCT05302843 ↗

Phase 1 Unknown 40 enrolled Betta Pharmaceuticals Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This is an open-labe Phase I study of BPI-28592 for the treatment of patients with solid tumors

Timeline

Start: 2021-03-22
Primary completion: 2023-12-31
Completion: 2023-12-31

Publications

Sheng J, Chen H, Fu B, Pan H, Wang J, Han W. BPI-28592 as a novel second generation inhibitor for NTRK fusion tumors. NPJ Precis Oncol. 2024 Sep 11;8(1):198. doi: 10.1038/s41698-024-00686-8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BPI-28592	Unknown	—	Oral

Indications